.. Épidémiologie-de-l-'ostéoporose, Incidence et prévalence de l, p.27

.. Les-techniques-d-'imagerie, 38 5.1.1 Méthodes de mesure de la densité osseuse, absorptiométrie biphotonique à rayons X (DXA).(9?11), p.40

.. Les-nouveaux-marqueurs-biologiques, 46 5.2.3.1 Les enzymes reflétant le nombre et l'activité ostéoclastique46 5.2.3.2 Les fragments urinaires de l'ostéocalcine46 5.2.3.3 Les régulateurs de l'activité ostéoclastique (RANk-L et ostéoprotégérine) Les régulateurs de l'activité ostéoblastique.(47), pp.37-4041

.. Nouveaux-inhibiteurs-de-la-résorption, 72 5.1.1 Inhibiteurs de RANKL(83?85), pp.87-9074

H. Guénard, Physiologie humaine. 3ème éd. Pradel, 2001.

T. Derrickson, Principes d'anatomie et de physiologie

T. Funck-brentano and M. Cohen-solal, Le vieillissement osseux : les nouveaux acteurs de communication intercellulaire. Médecine & Longévité, pp.200-204, 2010.
DOI : 10.1016/j.mlong.2010.05.001

K. Briot and C. Roux, Les marqueurs biochimiques du remodelage osseux. Gynécologie Obstétrique & Fertilité, pp.1009-1022, 2005.

C. Ribot, F. Trémollieres, and J. Pouillés, Aromatase et r??gulation du remodelage osseux, Revue du Rhumatisme, vol.73, issue.1, pp.32-40, 2006.
DOI : 10.1016/j.rhum.2005.02.010

P. Garnero, Nouveaux marqueurs biologiques du remodelage osseux dans l'ostéoporose. Médecine Nucléaire, pp.17-27, 2009.
DOI : 10.1016/j.mednuc.2008.09.008

D. Merlotti, L. Gennari, K. Stolakis, and R. Nuti, Aromatase Activity and Bone Loss in Men, Journal of Osteoporosis, vol.40, issue.6, p.230671, 2011.
DOI : 10.1210/en.2009-0540

H. Frost, Tetracycline-based histological analysis of bone remodeling, Calcified Tissue Research, vol.69, issue.1, pp.211-248, 1969.
DOI : 10.1007/BF02058664

R. Bartl, Osteoporose : prevention, diagnostic, traitement. Paris: Maloine, 2003.

É. Lespessailles, F. Cotté, C. Roux, P. Fardellone, F. Mercier et al., Prevalence and features of osteoporosis in the French general population: The Instant study, Joint Bone Spine, vol.76, issue.4, pp.394-400, 2009.
DOI : 10.1016/j.jbspin.2008.10.008

J. Bruder, J. Ma, J. Basler, and M. Welch, Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy, Urology, vol.67, issue.1, pp.152-157, 2006.
DOI : 10.1016/j.urology.2005.07.017

T. Beringer, Mortality and morbidity after hip fractures, BMJ, vol.308, issue.6924, p.343, 1994.
DOI : 10.1136/bmj.308.6924.343b

D. Curran, M. Maravic, P. Kiefer, V. Tochon, and P. Fardellone, Epidemiology of osteoporosis-related fractures in France: A literature review, Joint Bone Spine, vol.77, issue.6, pp.546-51, 2010.
DOI : 10.1016/j.jbspin.2010.02.006

M. Maravic, L. Bihan, C. Landais, P. Fardellone, and P. , Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database, Osteoporosis International, vol.13, issue.12, pp.1475-80, 2005.
DOI : 10.1007/s00198-005-2031-0

F. Borgström, N. Zethraeus, O. Johnell, L. Lidgren, S. Ponzer et al., Costs and quality of life associated with osteoporosis-related fractures in Sweden, Osteoporosis International, vol.7, issue.Suppl 2, pp.637-50, 2006.
DOI : 10.1007/s00198-005-0015-8

J. Compston, S. Papapoulos, and F. Blanchard, Report on Osteoporosis in the European Community: Current Status and Recommendations for the Future, Osteoporosis International, vol.8, issue.6, pp.531-535, 1998.
DOI : 10.1007/s001980050094

H. Blain, A. Vuillemin, A. Blain, F. Guillemin, D. Talance et al., Age-Related Femoral Bone Loss in Men: Evidence for Hyperparathyroidism and Insulin-Like Growth Factor-1 Deficiency, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol.59, issue.12, pp.1285-1294, 2004.
DOI : 10.1093/gerona/59.12.1285

M. Schürch, R. Rizzoli, B. Mermillod, H. Vasey, J. Michel et al., A prospective study on socioeconomic aspects of fracture of the proximal femur, Journal of Bone and Mineral Research, vol.307, issue.12, pp.1935-1977, 1996.
DOI : 10.1002/jbmr.5650111215

E. Canalis, G. Mazziotti, A. Giustina, and J. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteoporosis International, vol.89, issue.10, pp.1319-1347, 2007.
DOI : 10.1007/s00198-007-0394-0

D. Cohen-solall, Ost??oporose et h??parine, Revue du Rhumatisme, vol.68, issue.8, pp.727-735, 2001.
DOI : 10.1016/S1169-8330(01)00172-7

B. Kiratli, S. Srinivas, I. Perkash, and M. Terris, Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer, Urology, vol.57, issue.1, pp.127-159, 2001.
DOI : 10.1016/S0090-4295(00)00895-5

J. Body, Increased fracture rate in women with breast cancer: a review of the hidden risk, BMC Cancer, vol.122, issue.Suppl 1, p.384, 2011.
DOI : 10.1007/s10549-010-0935-7

R. Levasseur, E. Legrand, D. Chappard, and M. Audran, Contr??le central de la masse osseuse??: implications th??rapeutiques potentielles, Revue du Rhumatisme, vol.72, issue.10-11, pp.887-896, 2005.
DOI : 10.1016/j.rhum.2005.09.004

A. Fetique-will, T. Chevalley, and R. Rizzoli, inhibiteurs sélectifs de la recapture de la sérotonine et ostéoporose

Y. Yang, J. Lewis, S. Epstein, and D. Metz, Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture, JAMA, vol.296, issue.24, pp.2947-53, 2006.
DOI : 10.1001/jama.296.24.2947

L. Targownik, L. Lix, C. Metge, H. Prior, S. Leung et al., Use of proton pump inhibitors and risk of osteoporosis-related fractures, CMAJ août, vol.12179, issue.4, pp.319-345, 2008.

K. Berg, H. Kunins, J. Jackson, S. Nahvi, A. Chaudhry et al., Association Between Alcohol Consumption and Both Osteoporotic Fracture and Bone Density, The American Journal of Medicine, vol.121, issue.5, pp.406-424, 2008.
DOI : 10.1016/j.amjmed.2007.12.012

K. Briot and C. Roux, Les marqueurs biochimiques du remodelage osseux. Gynécologie Obstétrique & Fertilité, pp.1009-1022, 2005.

P. Garnero, Nouveaux marqueurs biologiques du remodelage osseux dans l'ostéoporose. Médecine Nucléaire, pp.17-27, 2009.
DOI : 10.1016/j.mednuc.2008.09.008

P. Delmas, Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs, Osteoporosis International, vol.11, issue.0, pp.66-76, 2000.
DOI : 10.1007/s001980070007

A. Nenonen, S. Cheng, K. Ivaska, S. Alatalo, T. Lehtimäki et al., Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover, Journal of Bone and Mineral Research, vol.133, issue.1, pp.1804-1816, 2005.
DOI : 10.1359/JBMR.050403

J. Halleen, S. Alatalo, H. Suominen, S. Cheng, A. Janckila et al., Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption, Journal of Bone and Mineral Research, vol.14, issue.7, pp.1337-1382, 2000.
DOI : 10.1359/jbmr.2000.15.7.1337

J. Halleen, M. Karp, S. Viloma, P. Laaksonen, J. Hellman et al., Two-Site Immunoassays for Osteoclastic Tartrate-Resistant Acid Phosphatase Based on Characterization of Six Monoclonal Antibodies, Journal of Bone and Mineral Research, vol.11, issue.Suppl 1, pp.464-473, 1999.
DOI : 10.1359/jbmr.1999.14.3.464

P. Gerdhem, K. Ivaska, S. Alatalo, J. Halleen, J. Hellman et al., Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women, Journal of Bone and Mineral Research, vol.3, issue.Suppl 6, pp.386-93, 2004.
DOI : 10.1359/JBMR.0301244

R. Christenson, Biochemical Markers of Bone Metabolism: An Overview, Clinical Biochemistry, vol.30, issue.8, pp.573-93, 1997.
DOI : 10.1016/S0009-9120(97)00113-6

A. Srivastava, S. Mohan, F. Singer, and D. Baylink, A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients, Bone, vol.31, issue.1, pp.62-71, 2002.
DOI : 10.1016/S8756-3282(02)00793-7

T. Ohashi, Y. Igarashi, Y. Mochizuki, T. Miura, N. Inaba et al., Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b, Clinica Chimica Acta, vol.376, issue.1-2, pp.205-217, 2007.
DOI : 10.1016/j.cca.2006.08.021

I. Byrjalsen, D. Leeming, P. Qvist, C. Christiansen, and M. Karsdal, Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies, Osteoporosis International, vol.15, issue.Suppl 1, pp.339-387, 2008.
DOI : 10.1007/s00198-007-0462-5

X. Wang, X. Shen, X. Li, and C. Agrawal, Age-related changes in the collagen network and toughness of bone, Bone, vol.31, issue.1, pp.1-7, 2002.
DOI : 10.1016/S8756-3282(01)00697-4

S. Roux, Nouvelles cibles thérapeutiques dans l'ostéoporose . Revue du Rhumatisme. 2010 ? mai, pp.257-63
DOI : 10.1016/j.rhum.2009.10.032

E. Sornay-rendu, F. Munoz, P. Garnero, F. Duboeuf, and P. Delmas, Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study, Journal of Bone and Mineral Research, vol.18, issue.Suppl 6, pp.1813-1822, 2005.
DOI : 10.1359/JBMR.050609

M. Bolland, A. Grey, A. Avenell, G. Gamble, and I. Reid, Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis, BMJ, vol.342, issue.apr19 1, pp.2040-2040
DOI : 10.1136/bmj.d2040

B. Dawson-hughes, S. Harris, E. Krall, and G. Dallal, Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or Older, New England Journal of Medicine, vol.337, issue.10, pp.670-676, 1997.
DOI : 10.1056/NEJM199709043371003

C. Potier-de, Estimation du statut en vitamines et minéraux de la population française d'après des enquêtes récentes, pp.77-87, 1999.

V. Breuil and L. Eullerziegler, Nutrition et vieillissement osseuxL'ostéoporose. Nutrition Clinique et Métabolisme, pp.212-220, 2004.
DOI : 10.1016/j.nupar.2004.10.005

V. Coxam, Ost??oporose et pr??vention nutritionnelle, EMC - Endocrinologie - Nutrition, vol.7, issue.3, 2010.
DOI : 10.1016/S1155-1941(10)51201-0

N. Shaw, Bisphosphonate treatment of bone disease Archives of Disease in Childhood, pp.494-503, 2005.

R. Russell, Bisphosphonates: Mode of Action and Pharmacology, PEDIATRICS, vol.119, issue.Supplement, pp.150-162, 2007.
DOI : 10.1542/peds.2006-2023H

C. Benhamou, Effets des??traitements de??l'ost??oporose sur??la??qualit?? osseuse, Revue du Rhumatisme, vol.74, issue.1, pp.43-51, 2007.
DOI : 10.1016/j.rhum.2006.06.008

S. Kim, S. Schneeweiss, J. Katz, R. Levin, and D. Solomon, Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort, Journal of Bone and Mineral Research, vol.280, issue.(Suppl 3), pp.993-1001, 2011.
DOI : 10.1002/jbmr.288

B. Kuehn, Studies Probe Possible Link Between Bisphosphonates and Femoral Fractures, JAMA, vol.303, issue.18
DOI : 10.1001/jama.2010.576

W. Pdf, Available de, Internet]. [cité 2012 févr 2]Press_release, 2011.

E. Legrand, E. Hoppe, D. Chappard, and M. Audran, Les SERMs dans le traitement de l'ostéoporose : état des lieux et perspectives. Gynécologie Obstétrique & Fertilité, pp.423-431, 2006.
DOI : 10.1016/j.gyobfe.2006.03.004

V. Viereck, C. Gründker, S. Blaschke, B. Niederkleine, H. Siggelkow et al., Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.9, pp.4206-4219, 2003.
DOI : 10.1210/jc.2002-021877

B. Ettinger, D. Black, B. Mitlak, R. Knickerbocker, T. Nickelsen et al., Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, pp.637-682, 1999.
DOI : 10.1001/jama.282.7.637

S. Olivier, M. Fillet, M. Malaise, J. Piette, V. Bours et al., Sodium nitroprussideinduced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene, Biochem. Pharmacol. mars, vol.1569, issue.6, pp.891-901, 2005.

M. Talbert, G. Willoquet, and R. Gervais, Le guide pharmaco clinique. Rueil-Malmaison: le Moniteur des pharmacies, 2009.

Y. Ma, R. Cain, D. Halladay, X. Yang, Q. Zeng et al., Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation, Endocrinology, vol.142, issue.9, pp.4047-54, 2001.
DOI : 10.1210/en.142.9.4047

C. Tam, J. Heersche, T. Murray, and J. Parsons, Parathyroid Hormone Stimulates the Bone Apposition Rate Independently of Its Resorptive Action: Differential Effects of Intermittent and Continuous Administration*, Endocrinology, vol.110, issue.2, pp.506-518, 1982.
DOI : 10.1210/endo-110-2-506

M. Rubin, F. Cosman, R. Lindsay, and J. Bilezikian, The Anabolic Effects of Parathyroid Hormone, Osteoporosis International, vol.13, issue.4, pp.267-77, 2002.
DOI : 10.1007/s001980200026

C. Cormier, Rôle de la parathormone dans l'ostéoporose. La Presse Médicale, pp.495-501, 2006.

R. Neer, C. Arnaud, J. Zanchetta, R. Prince, G. Gaich et al., Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, New England Journal of Medicine, vol.344, issue.19, pp.1434-1475, 2001.
DOI : 10.1056/NEJM200105103441904

S. Greenspan, H. Bone, M. Ettinger, D. Hanley, R. Lindsay et al., Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis, Annals of Internal Medicine, vol.146, issue.5, pp.326-365, 2007.
DOI : 10.7326/0003-4819-146-5-200703060-00005

F. Cosman, J. Nieves, L. Woelfert, V. Shen, and R. Lindsay, Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women, Journal of Bone and Mineral Research, vol.132, issue.Suppl 1, pp.1051-1056, 1998.
DOI : 10.1359/jbmr.1998.13.6.1051

P. Meunier, C. Roux, S. Ortolani, M. Diaz-curiel, J. Compston et al., Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis, Osteoporosis International, vol.17, issue.12, pp.1663-73, 2009.
DOI : 10.1007/s00198-008-0825-6

B. Cortet, Ran??late de strontium : une nouvelle approche de l'ost??oporose post-m??nopausique, Revue du Rhumatisme, vol.72, issue.S1, pp.16-22, 2005.
DOI : 10.1016/S1169-8330(05)80004-3

A. Jonville-bera and E. Autret-leca, Ran??late de strontium (Protelos??)??: effets ind??sirables rapport??s en France, La Presse M??dicale, vol.40, issue.10, pp.453-462, 2011.
DOI : 10.1016/j.lpm.2011.07.010

S. Roux, Nouvelles cibles thérapeutiques dans l'ostéoporose . Revue du Rhumatisme. 2010 ? mai, pp.257-63
DOI : 10.1016/j.rhum.2009.10.032

S. Cummings, J. Martin, M. Mcclung, E. Siris, R. Eastell et al., Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis, New England Journal of Medicine, vol.361, issue.8, pp.756-65, 2009.
DOI : 10.1056/NEJMoa0809493

M. Quemerais-durieu, V. Kerlan, and O. Chabre, Innovations thérapeutiques dans l'ostéoporose (anticorps antisclérostine et denosumab) Annales d'Endocrinologie, pp.15-22, 2011.
DOI : 10.1016/s0003-4266(11)70005-1

H. Bone, M. Mcclung, C. Roux, R. Recker, J. Eisman et al., Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density, Journal of Bone and Mineral Research, pp.091029141139034-41, 2009.
DOI : 10.1359/jbmr.091035

S. Frisch and R. Screaton, Anoikis mechanisms, Current Opinion in Cell Biology, vol.13, issue.5, pp.555-62, 2001.
DOI : 10.1016/S0955-0674(00)00251-9

M. Murphy, K. Cerchio, S. Stoch, K. Gottesdiener, M. Wu et al., Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.4, pp.2022-2030, 2005.
DOI : 10.1210/jc.2004-2126

M. Lark, G. Stroup, S. Hwang, I. James, D. Rieman et al., Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis, J. Pharmacol. Exp. Ther, vol.291, issue.2, pp.612-619, 1999.

H. Zhao, F. Ross, and S. Teitelbaum, Integrin Regulates Osteoclast Apoptosis by Transmitting a Positive Death Signal, Molecular Endocrinology, vol.19, issue.3, pp.771-80, 2005.
DOI : 10.1210/me.2004-0161

A. Hodsman, D. Bauer, D. Dempster, L. Dian, D. Hanley et al., Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use, Endocrine Reviews, vol.26, issue.5, pp.688-703, 2005.
DOI : 10.1210/er.2004-0006

L. Fitzpatrick, C. Dabrowski, G. Cicconetti, D. Gordon, S. Papapoulos et al., The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.8, pp.2441-2450, 2011.
DOI : 10.1210/jc.2010-2855

D. Winkler, M. Sutherland, J. Geoghegan, C. Yu, T. Hayes et al., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist, The EMBO Journal, vol.262, issue.23, pp.6267-76, 2003.
DOI : 10.1093/emboj/cdg599

X. Li, M. Ominsky, K. Warmington, S. Morony, J. Gong et al., Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*, Journal of Bone and Mineral Research, vol.24, issue.4, pp.578-88, 2009.
DOI : 10.1359/jbmr.081206

B. Macdonald, D. Joiner, S. Oyserman, P. Sharma, S. Goldstein et al., Bone mass is inversely proportional to Dkk1 levels in mice, Bone, vol.41, issue.3, pp.331-340, 2007.
DOI : 10.1016/j.bone.2007.05.009

H. Glantschnig, R. Hampton, P. Lu, J. Zhao, S. Vitelli et al., Generation and Selection of Novel Fully Human Monoclonal Antibodies That Neutralize Dickkopf-1 (DKK1) Inhibitory Function in Vitro and Increase Bone Mass in Vivo, Journal of Biological Chemistry, vol.285, issue.51, pp.40135-40182, 2010.
DOI : 10.1074/jbc.M110.166892

B. Cortet and O. Bénichou, Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine, pp.1-7, 2006.

J. Cramer, N. Lynch, A. Gaudin, M. Walker, and W. Cowell, The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France, Clinical Therapeutics, vol.28, issue.10, pp.1686-94, 2006.
DOI : 10.1016/j.clinthera.2006.10.013